ANIP - ANI Pharmaceuticals Inc Debt to Book Capitalization Ratio

Graphic logo of ANI Pharmaceuticals Inc (ANIP)

ANI Pharmaceuticals (ANIP) bases its production on strict environmental oversight of substance synthesis, minimizing water consumption and safely disposing of chemicals. The brand has earned the trust of pharmacies as a stable supplier of high-quality prescription drugs and niche generics. Scaling the assortment of rare medicines optimizes costs, and the current figure stands at 0.97. This chart illustrates the company's financial dynamics.

ANIP (ANI Pharmaceuticals Corp) Debt to Book Value history from 07/04/2022 to 10/27/2026
Core merchandise of ANI Pharma

This ratio reflects the proportion of total liabilities to equity, allowing for an assessment of the degree of financial leverage and the stability of the company's financing structure. By analyzing the levels of financial dependence based on book capital, an investor determines the balance between debt load and profitability, which is critical for maintaining generic production and developing the high-margin segment of drugs for the treatment of rare autoimmune diseases at ANI Pharmaceuticals (ANIP).

Competitors of ANI Pharmaceuticals

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|MNKD: Debt to Book Capitalization Ratio|AMPH - Debts to Book Value|Debt to Book Value Pacira BioSciences PCRX|SPRY - Debt to Book Capital|Debts to Book Capitalization Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Debt to Net Assets Ratio|Debts to Book Capitalization SCPH (scPharmaceuticals, Inc.)|Debts to Book Value TECX|Tonix Pharmaceuticals (TNXP) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio sxtchina.com (SXTC)|Debts to Book Capitalization EPRX (Eupraxia Pharmaceuticals Inc.)|BioHarvest Sciences, Inc. - Debts to Book Capitalization|Invizyne Technologies, Inc. (EXOZ) - Debt to Book Capitalization Ratio|ORMP - Debt to Book Value Ratio|enterabio.com - Debts to Book Capitalization|Debts to Net Assets ipatherapeutics.com|ABVC - Debt to Book Value|Debt to Net Assets Ratio CPIX|QNTM - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio FibroGen Corporation (FGEN)|Debts to Book Capitalization Telomir Pharmaceuticals|Debt to Net Assets Ratio Rani Therapeutics Holdings RANI|Synergy CHC Corporation - Debts to Book Capitalization|RLYB: Debts to Book Capitalization|Debt to Book Capitalization Ratio lexariabioscience.com LEXX|PULM (Pulmatrix Corporation) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio PTHL|Debt to Book Value Aptorum|Debts to Book Capitalization LYRA|Debts to Book Capitalization Impact BioMedical, Inc. (IBO)|TNF Pharmaceuticals, Inc. - Debts to Book Capitalization|Debt to Book Value cbdMD Inc. YCBD|PRFX (PainReform Ltd.) - Debts to Book Capitalization|Altamira Therapeutics (CYTO) - Debts to Book Value|LIPO: Debt to Book Value|Debts to Book Capitalization OptiNose Inc|Pieris (PIRS) - Debt to Book Value|Debt to Book Capital Procaps Group Corp|PTPI (Petros Pharmaceuticals) - Debts to Book Capitalization|Debts to Net Assets qlsyy.net (QLI)|ACELYRIN - Debts to Book Capitalization|Debt to Book Value TFF Pharmaceuticals Inc. TFFP